About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 395912, 8 pages
http://dx.doi.org/10.1155/2012/395912
Research Article

Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases

1Key Laboratory of Contraceptives and Devices Research (NPFPC), Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices, Shanghai Institute of Planned Parenthood Research, Shanghai 200032, China
2Laboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, China
3Pharmacy College, Jinan University, Guangzhou 510632, China
4Occupational and Environmental Health Department, Dalian Medical University, Dalian 116044, China

Received 19 July 2012; Accepted 14 September 2012

Academic Editor: Gerhard Litscher

Copyright © 2012 Yun-Feng Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Wu, E. J. Lien, and L. L. Lien, “Chemical and pharmacological investigations of Epimedium species: a survey,” Progress in Drug Research, vol. 60, pp. 1–57, 2003. View at Scopus
  2. J. H. Kim, Y. J. Mun, S. J. Im, J. H. Han, H. S. Lee, and W. H. Woo, “Effects of the aqueous extract of Epimedii Herba on the antibody responses in mice,” International Immunopharmacology, vol. 1, no. 5, pp. 935–944, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Ning, Z. C. Xin, G. Lin, L. Banie, T. F. Lue, and C. S. Lin, “Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells,” Urology, vol. 68, no. 6, pp. 1350–1354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. H. B. Xu and Z. Q. Huang, “Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro,” Vascular Pharmacology, vol. 47, no. 1, pp. 18–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. B. Zhang and Q. T. Yang, “The testosterone mimetic properties of icariin,” Asian Journal of Andrology, vol. 8, no. 5, pp. 601–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. L. C. Wienkers and T. G. Heath, “Predicting in vivo drug interactions from in vitro drug discovery data,” Nature Reviews Drug Discovery, vol. 4, no. 10, pp. 825–833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. K. H. Liu, M. J. Kim, B. H. Jeon et al., “Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 1, pp. 83–91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Jancova, P. Anzenbacher, and E. Anzenbacherova, “Phase II drug metabolizing enzymes,” Biomedical Papers, vol. 154, no. 2, pp. 103–116, 2010.
  9. J. A. Williams, R. Hyland, B. C. Jones et al., “Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC 1/AUC) ratios,” Drug Metabolism and Disposition, vol. 32, no. 11, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Liu, J. Ramírez, L. House, and M. J. Ratain, “Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 32–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Liu, J. Ramírez, and M. J. Ratain, “Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors,” British Journal of Clinical Pharmacology, vol. 71, no. 6, pp. 917–920, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. O. Miners, P. I. MacKenzie, and K. M. Knights, “The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitroin vivo extrapolation of drug clearance and drug-drug interaction potential,” Drug Metabolism Reviews, vol. 42, no. 1, pp. 196–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. K. L. Kiang, M. H. H. Ensom, and T. K. H. Chang, “UDP-glucuronosyltransferases and clinical drug-drug interactions,” Pharmacology and Therapeutics, vol. 106, no. 1, pp. 97–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Hasegawa, “Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid,” Journal of Pharmacological Sciences, vol. 95, no. 2, pp. 153–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Liu, W. Li, P. Li, M. C. Deng, S. L. Yang, and L. Yang, “The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity,” Biological and Pharmaceutical Bulletin, vol. 27, no. 10, pp. 1555–1560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, H. Ma, J. W. Zhang, M. C. Deng, and L. Yang, “Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes,” Planta Medica, vol. 72, no. 2, pp. 126–131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Liu and L. Yang, “Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics,” Journal of Zhejiang University B, vol. 7, no. 2, pp. 99–106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Liu, J. W. Zhang, W. Li et al., “Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes,” Toxicological Sciences, vol. 91, no. 2, pp. 356–364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Wu, C. Z. Ai, Y. Liu, et al., “Interactions between Phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes,” Current Drug Metabolism, vol. 13, no. 5, pp. 599–614, 2012.
  20. V. Uchaipichat, P. I. Mackenzie, D. J. Elliot, and J. O. Miners, “Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases,” Drug Metabolism and Disposition, vol. 34, no. 3, pp. 449–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. K. E. Thummel and G. R. Wilkinson, “In vitro and in vivo drug interactions involving human CYP3A,” Annual Review of Pharmacology and Toxicology, vol. 38, pp. 389–430, 1998. View at Scopus
  22. R. A. Copeland, Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, Wiley, New York, NY, USA, 2000.
  23. B. Davies and T. Morris, “Physiological parameters in laboratory animals and humans,” Pharmaceutical Research, vol. 10, no. 7, pp. 1093–1095, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Ye, J. Chen, and S. Liu, “Pharmacokinetics of icariin in rats,” Chinese Pharmaceutical Journal, vol. 34, no. 1, pp. 33–36, 1999. View at Scopus
  25. Y. Cai, X.-B. Jia, Y. Chen, C. Y. Fan, and L. X. Huang, “Absorption and metabolism of icariin in the in situ single-pass perfused rat intestinal model,” Chinese Pharmaceutical Journal, vol. 44, no. 13, pp. 985–988, 2009. View at Scopus
  26. W. Xu, Y. P. Zhang, M. Yang et al., “LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 45, no. 4, pp. 667–672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Shen, S. P. Wong, and E. L. Yong, “Sensitive and rapid method to quantify icaritin and desmethylicaritin in human serum using gas chromatography-mass spectrometry,” Journal of Chromatography B, vol. 857, no. 1, pp. 47–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. T. D. Bjornsson, J. T. Callaghan, H. J. Einolf et al., “The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective,” Drug Metabolism and Disposition, vol. 31, no. 7, pp. 815–832, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Nagar and R. P. Remmel, “Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer,” Oncogene, vol. 25, no. 11, pp. 1659–1672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. K. Ritter, “Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics,” Expert Opinion on Drug Metabolism and Toxicology, vol. 3, no. 1, pp. 93–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi, “Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines,” Drug Metabolism and Disposition, vol. 36, no. 8, pp. 1461–1464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Ohno and S. Nakajin, “Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 32–40, 2009. View at Publisher · View at Google Scholar · View at Scopus